Hyperhomocysteinemia and the risk of silent brain infarcts: systematic review and meta-analysis.

J Stroke Cerebrovasc DisJul 30, 2026 (epub)
Clinical ResearchNeurology

Mahmoud Afia, Alaa Abdelraheam, Sai Krishna Vallamchetla et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the association between hyperhomocysteinemia and silent brain infarcts in 2331 patients. The study found that the rate of silent brain infarcts was 23.4% in patients with hyperhomocysteinemia compared to 22.8% in those with normal levels, yielding an odds ratio of 1.84 (95% CI 1.09-3.11; P = 0.02).

Key findings

  • Silent brain infarct rate was 23.4% in hyperhomocysteinemia patients versus 22.8% in controls.
  • Odds ratio for silent brain infarcts in hyperhomocysteinemia was 1.84 (95% CI 1.09-3.11; P = 0.02).
  • Higher association observed with >12 μmol/L homocysteinemia cutoff (OR 3.08; P < 0.0001).
  • MMSE scores were numerically lower in hyperhomocysteinemia patients, but not significantly different.

Why it matters

Understanding the relationship between hyperhomocysteinemia and silent brain infarcts is crucial for identifying potential risk factors for cognitive decline and stroke. This may inform future therapeutic strategies aimed at modifying homocysteine levels.

Source

PubMed · PMID 42532456

Published in J Stroke Cerebrovasc Dis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.